Magenta Therapeutics, Inc (MGTA)

Etorro trading 970x250
Magenta Therapeutics, Inc (MGTA) Logo

About Magenta Therapeutics, Inc

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent prophylaxis of graft-versus-host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate potential utility of MGTA-117 for conditioning of patients receiving one or more investigational lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 100 Technology Square, Cambridge, MA, United States, 02139

Magenta Therapeutics, Inc News and around…

Latest news about Magenta Therapeutics, Inc (MGTA) common stock and company :

Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
04 Oct, 2021 FinancialContent

Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company’s Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives.

Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
21 Sep, 2021 FinancialContent

Magenta Therapeutics, Inc. (Nasdaq:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28 at 4:40 p.m. ET.

Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial
15 Sep, 2021 FinancialContent

TheFDA has signed offMagenta Therapeutics Inc's(NASDAQ: MGTA) IND application for MGTA-117. Related ...

Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
15 Sep, 2021 FinancialContent

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced today that its Investigational New Drug (IND) application for MGTA-117 is active with the U.S. Food and Drug Administration (FDA). The company expects to open the Phase 1/2 clinical trial in Q4 2021 to evaluate its MGTA-117 antibody-drug conjugate (ADC) targeted conditioning program.

Analysts See 18% Upside For The Holdings of VTWV
27 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $164.96 per unit.

How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own?
09 Aug, 2021 Yahoo! Finance

A look at the shareholders of Magenta Therapeutics, Inc. ( NASDAQ:MGTA ) can tell us which group is most powerful...

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
05 Aug, 2021 FinancialContent

During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest ...

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
05 Aug, 2021 FinancialContent

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the second quarter ended June 30, 2021, and recent program highlights.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
03 Aug, 2021 Yahoo! Finance

Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021
03 Aug, 2021 FinancialContent

Upgrades For SolarEdge Technologies Inc (NASDAQ:SEDG), Johnson Rice upgraded the previous rating of Hold to Accumulate. ...

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
03 Aug, 2021 FinancialContent

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
03 Aug, 2021 Yahoo! Finance

CAMBRIDGE, Mass., August 03, 2021--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:

Were Hedge Funds Right About Magenta Therapeutics, Inc. (MGTA)?
30 Jul, 2021 Yahoo! Finance

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
27 Jul, 2021 FinancialContent
MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Magenta Therapeutics, Inc. Investigation
23 Jul, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / July 23, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ('Magenta' or the 'Company') (NASDAQ:MGTA).

2 “Strong Buy” Stocks Under $10 With Strong Growth Prospects
23 Jul, 2021 Yahoo! Finance

The key to profitable investing is building a profile that combines powerful potential with an economical point of entry. It’s a strategy that will frequently suggest a closer look at stocks in the micro- and small-cap size range, companies with valuations less than $2 billion. These smaller firms frequently feature share prices below $10, and triple-digit upsides to sweeten the pot. Using TipRanks' database, we've found two stocks that fit this profile: A market cap under $500 million and a sha

Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company
22 Jul, 2021 FinancialContent
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Investigation
21 Jul, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / July 21, 2021 / July Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA).

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
21 Jul, 2021 FinancialContent

Gainers Chembio Diagnostics (NASDAQ: CEMI) shares rose 102.91% to $4.18 during Wednesday's pre-market session. The market value of ...

Magenta Therapeutics Stock Drops As FDA Issues Clinical Hold On Blood Cancer Candidate IND
21 Jul, 2021 FinancialContent

TheFDA has instituted a clinical holdonMagenta Therapeutics Inc's(NASDAQ: MGTA) Investigational New Drug ...

Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
21 Jul, 2021 FinancialContent

Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

After Plunging 21% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)
14 Jul, 2021 Yahoo! Finance

Magenta Therapeutics, Inc. (MGTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
07 Jul, 2021 FinancialContent

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4’s Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company.

MGTA Makes Notable Cross Below Critical Moving Average
06 Jul, 2021 FinancialContent

In trading on Tuesday, shares of Magenta Therapeutics Inc (MGTA) crossed below their 200 day moving average of $9.55, changing hands as low as $9.49 per share. Magenta Therapeutics Inc shares are currently trading down about 3.5% on the day..

Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
06 Jul, 2021 FinancialContent

Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company’s first Chief Commercial Officer.

Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
29 Jun, 2021 FinancialContent

Upgrades For Nutrien Ltd (NYSE:NTR), Susquehanna upgraded the previous rating of Neutral to Positive. In the first ...

Gene Therapy Companies Undervalued, Positioned for Upside
17 Jun, 2021 Yahoo! Finance

Pharmaceutical companies can trade sideways for years, and may see a spike every now and then due to positive announcements or an FDA approval update. The newest subset of the biotech industry, known as gene therapy companies, has been multiplying at an astonishing rate. As a result, they have many new stocks listed to capital markets. These companies have recently piqued the interest of investors, and analysts are weighing in. Many individuals are born with disorders for which there is no cure,

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
15 Jun, 2021 FinancialContent

Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to ...

Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
14 Jun, 2021 FinancialContent

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Thomas Beetham as Chief Legal Officer.

Magenta Therapeutics, Inc (MGTA) is a NASDAQ Common Stock listed in , ,

970x250